Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Zymeworks Inc. Closes the Market

ZYME

Canada NewsWire

TORONTO, June 2, 2017 /CNW/ - Dr. Ali Tehrani, President & Chief Executive Officer, Zymeworks Inc. (ZYME), joined Ungad Chadda, President, Capital Formation, Equity Capital Markets, TMX Group to close the market. Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer.  Zymeworks Inc. commenced trading on Toronto Stock Exchange on May 3, 2017.

Dr. Ali Tehrani, President & Chief Executive Officer, Zymeworks Inc. (ZYME), joined Ungad Chadda, President, Capital Formation, Equity Capital Markets, TMX Group to close the market. Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. Zymeworks Inc. commenced trading on Toronto Stock Exchange on May 3, 2017. (CNW Group/TMX Group Limited)

SOURCE TMX Group Limited

View original content with multimedia: http://www.newswire.ca/en/releases/archive/June2017/04/c8990.html



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today